Citation: | GUO Qiuyun, YU Shiying. Comparison of Lorazepam,Diphenhydramine,Haloperidol Combined with Tropisetron and Dexamethasone Combined with Tropisetron Efficacy in Preventing Emesis Induced by Highly Emetogenic Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 798-800. DOI: 10.3971/j.issn.1000-8578.2013.08.017 |
[1] |
Decker GM, DeMeyer ES, Kisko DL.Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy[J].J Support Oncol,2006 ,4(1):35-41, 52.
|
[2] |
Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach[J]. Support Care Cancer, 2002,10(7):519-22.
|
[3] |
Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control[J]. Oncologist,2003,8(2):187-98.
|
[4] |
Jordan K, Kasper C,Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment[J]. Eur J Cancer,2005,41(2):199-205.
|
[5] |
Aapro M, Molassiotis A, Dicato M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)[J].Ann Oncol,2012,23(8):1986-92.
|
[6] |
Fernández-Ortega P, Caloto MT, Chirveches E, et al. Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life[J]. Support Care Cancer,2012,20(12):3141-8.
|
[7] |
Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting[J]. Ann N Y Acad Sci,2011,1222:40-8.
|
[8] |
Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy[J].Br J Cancer,2006,94(7):1011-5.
|
[9] |
Prommer E.Role of haloperidol in palliative medicine: an update[J].Am J Hosp Palliat Care, 2012,29(4):295-301.
|
[10] |
Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam[J].Clin Pharmacokinet,1981,6(2):89-105.
|
[11] |
Friedlander ML, Kearsley JH, Sims K, et al.Lorazepam as an adjunct to antiemetic therapy with haloperidol in patients receiving cytotoxic chemotherapy[J]. Aust N Z J Med, 1983,13(1):53-6.
|
[12] |
Davies A, Adena MA, Keks NA, et al. Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety [J].Clin Ther,1998,20(1):58-71.
|
[13] |
Weschules DJ. Tolerability of the compound ABHR in hospice patients[J]. J Palliat Med, 2008,8(6):1135-43.
|
[14] |
Moon RB. ABHR gel in the treatment of nausea and vomiting in the hospice patient[J]. Int J Pharm Compounding,2006,10:95-9.
|
[15] |
Bleicher J, Bhaskara A, Huyck T, et al. Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy- induced nausea/vomiting: results of two pilot trials[J].J Support Oncol,2008,6(1):27-32.
|